Medical Devices

Flagship Applications

Leukocyte Inhibition Module (LIM)

  • LEUKOCARE’s Leukocyte Inhibition Module (LIM) is  designed for insertion into extracorporeal blood circuits
  • Activation of leukocytes is limited by transient contact with a surface coupled protein

LEUKOCARE’s Leukocyte Inhibition Module was clinically tested and has been successfully licensed out

Back
The LIM is designed for insertion into extracorporeal blood circuits. Activation of leukocytes is limited by transient contact with a surface coupled protein inducing inactivation and apoptosis of activated granulocytes

Schematic diagram outlining the mode of action of LEUKOCARE’s Leukocyte Inhibition Module (LIM): the LIM is designed for insertion into extracorporeal blood circuits.

Activation of leukocytes is limited by transient contact with a surface coupled protein inducing inactivation and apoptosis of activated granulocytes resulting in reduced systemic inflammation.

An anti-inflammatory surface coating based on the LIM technology has been successfully licensed to Xenios, a partner in the medical device industry (s. press releases 2013).